Geographic variation in sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia

Ähnliche Einträge

• Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?
  von: Tamara Y. Milder, et al.
  Veröffentlicht: (2024)
• Medication adherence to sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide‐1 receptor agonists: A meta‐analysis
  von: Conner E. Johnson, et al.
  Veröffentlicht: (2024)
• Comparative effectiveness of insulin glargine, glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors in veterans with type 2 diabetes
  von: Jincheng Shen, et al.
  Veröffentlicht: (2025)
• Elective peri‐operative management of adults taking glucagon‐like peptide‐1 receptor agonists, glucose‐dependent insulinotropic peptide agonists and sodium‐glucose cotransporter‐2 inhibitors: a multidisciplinary consensus statement
  von: Kariem El‐Boghdadly, et al.
  Veröffentlicht: (2025)
• Gastric ultrasound and mitigating risk of glucagon‐like peptide‐1 receptor agonists: a reply
  von: Peter C.‐A. Kam, et al.
  Veröffentlicht: (2024)